Brian Adams appointed as Kymera’s CLO and Corporate Secretary
Ella Day | September 11, 2025 | Appointment | | Kymera, biopharma, corporate, immunology
Brian Adams has been appointed as Kymera Therapeutics’ Chief Legal Officer (CLO) and Corporate Secretary. He will lead Kymera’s legal, governance and intellectual property functions.
Kymera is a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases.
Adams has nearly two decades of leadership in the life sciences, spanning corporate development, strategic planning and governance. Previously, Adams was CLO of Relay Therapeutics. He has also held senior roles at Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology and Genzyme Corporation.
Adams succeeds Ellen Chiniara, who is retiring from her role to focus on board service, mentoring and other advisory opportunities.
Nello Mainolfi, Founder, President and CEO, Kymera Therapeutics said: “Brian’s proven leadership and deep expertise will be instrumental as we advance and scale our novel programmes through clinical development and toward commercialisation.”
He added: “Additionally, we would like to sincerely thank Ellen for her strong dedication and many contributions to Kymera’s success throughout the company’s remarkable growth and wish her the best as she pursues her next chapter.”
Adams said: “I am thrilled to be joining the company at such an exciting time of progress and look forward to working with this pioneering team as we strive to redefine what’s possible in immunology with groundbreaking oral medicines.”
This article featured in: October 2025 – The Pharmafile Brief
Related Content
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
The current forms of immunotherapy, how T cell therapy works and what the future holds
Symeres announces acquisition of DGr Pharma
Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in …
